Skip to main content

Table 1 Number of individuals with observed alleles in respective genes by allele group

From: Next-generation sequencing profiling of mitochondrial genomes in gout

Gene

Group 1

Group 2

Group 3

Gout

n (%)

Non-gout

n (%)

P

Gout

n (%)

P

Non-gout

n (%)

P

MT-ATP6

40 (76.92)

69 (66.35)

0.175

10 (19.23)

9.03 × 10−6

25 (24.04)

1.14 × 10−4

MT-ATP8

4 (7.69)

12 (11.54)

0.455

2 (3.85)

1.10 × 10−1

12 (11.54)

8.86 × 10−3

MT-CO1

26 (50.00)

48 (46.15)

0.650

14 (26.92)

5.56 × 10−8

39 (37.50)

3.41 × 10−7

MT-CO2

14 (26.92)

20 (19.23)

0.273

12 (23.08)

7.34 × 10−7

20 (19.23)

7.07 × 10−4

MT-CO3

42 (80.77)

78 (75.00)

0.420

6 (11.54)

1.12 × 10−3

17 (16.35)

2.01 × 10− 3

MT-CYB

52 (100.00)

104 (100.00)

1.000

10 (19.23)

9.03 × 10−6

40 (38.46)

2.15 × 10−7

MT-ND1

33 (63.46)

57 (54.81)

0.302

9 (17.31)

3.09 × 10−5

19 (18.27)

1.01 × 10−3

MT-ND2

37 (71.15)

69 (66.35)

0.544

8 (15.38)

1.04 × 10−4

22 (21.15)

3.46 × 10− 4

MT-ND3

46 (88.46)

88 (84.62)

0.515

2 (3.85)

1.10 × 10−1

17 (16.35)

2.01 × 10−3

MT-ND4

52 (100.00)

104 (100.00)

1.000

7 (13.46)

3.44 × 10−2

30 (28.85)

1.64 × 10−5

MT-ND4L

11 (21.15)

19 (18.27)

0.667

0 (0.00)

1.000

9 (8.65)

2.98× 10−2

MT-ND5

46 (88.46)

99 (95.19)

0.182

15 (28.85)

8.35 × 10−9

32 (30.77)

7.24 × 10−6

MT-ND6

31 (59.62)

57 (54.81)

0.568

9 (17.31)

3.09 × 10−5

18 (17.31)

1.42 × 10−3

MT-RNR1

35 (67.31)

74 (71.15)

0.622

4 (7.69)

1.14 × 10−2

20 (19.23)

7.07 × 10−4

MT-RNR2

52 (100.00)

104 (100.00)

1.000

5 (9.62)

3.60 × 10−3

25 (24.04)

1.14 × 10−4

MT-TRNA a

26 (50.00)

54 (51.92)

0.821

18 (34.62)

1.78 × 10−10

28 (26.92)

3.62 × 10−5

  1. For each gene, numbers and percentages of samples from patients with gout/non-gout with alleles of the respective gene that fall in each group are presented. Group 1, alleles shared by patients with gout and non-gout controls. Group 2, alleles in patients with gout only. Group 3, alleles found in non-gout controls only
  2. aPlease refer to Additional file 2 for more detailed information